About the Authors

Tram T. Tran

Tram.Tran@cshs.org

Affiliation Liver Disease and Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, United States of America

Stuart C. Gordon

Affiliation Division of Hepatology, Henry Ford Hospital, Detroit, Michigan, United States of America

Scott Fung

Affiliation Department of Medicine, University of Toronto, Toronto, Canada

Phillip Dinh

Affiliation Gilead Sciences, Foster City, California, United States of America

Leland Yee

Affiliation Gilead Sciences, Foster City, California, United States of America

Eduardo Bruno Martins

Affiliation Gilead Sciences, Foster City, California, United States of America

Maria Buti

Affiliation Department of Hepatology, Hospital General Universitario Valle Hebron and Ciberehd del Instituto Carlos III, Barcelona, Spain

Patrick Marcellin

Affiliation Department of Hepatologie, University of Paris, Paris, France

Competing Interests

The authors have read the journal's policy and the authors of this manuscript have the following competing interests: SG has received grant/research support from AbbVie pharmaceuticals, Bristol-Myers Squibb, CVS Caremark, Gilead Sciences Ltd, GlaxoSmithKline, Intercept Pharmaceuticals, Merck, Novartis and Vertex; acted as a consultant for, Bristol-Myers Squibb, CVS Caremark, Gilead Sciences Ltd, GlaxoSmithKline, Novartis and Vertex Pharmaceuticals; and serves on the data monitoring board for Tibotex-Janssen. SF has acted as a consultant, advisor and speaker for Gilead Sciences Ltd and as an advisor and speaker for Merck and Vertex Pharmaceuticals. PD is an employee and stock holder of Gilead Sciences Ltd. LY is an employee and stock holder of Gilead Sciences Ltd. EBM is an employee and stock holder of Gilead Sciences Ltd. MB acts an advisor for Gilead Sciences Ltd, Bristol-Myers Squibb and Novartis. PM has worked with Bristol-Myers Squibb, Gilead Sciences Ltd, Janssen-Tibotec, Merck, Novartis, Roche Pharmaceuticals and Vertex Pharmaceuticals. He has also acted as an investigator for Boehringer Ingelheim and Pfizer, an investigator and expert for Abbott and acted as an investigator and received grant support from Alios BioPharma. TT has no conflicts of interest. The affiliation for Dr Gordon has been amended to ‘Henry Ford Hospital’. This is not a commercial company. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: TT LY EBM. Analyzed the data: TT SG SF LY EBM MB PM. Contributed reagents/materials/analysis tools: TT SG SF PD LY EBM MB PM. Wrote the paper: TT SG SF PD LY EBM MB PM. Approval of final version for publication: TT SG SF PD LY EBM MB PM.